

paulo De sepulveda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1578850/publications.pdf>

Version: 2024-02-01

36
papers

1,610
citations

304743

22
h-index

377865

34
g-index

38
all docs

38
docs citations

38
times ranked

2042
citing authors

#	ARTICLE	IF	CITATIONS
1	Socs1 binds to multiple signalling proteins and suppresses Steel factor-dependent proliferation. EMBO Journal, 1999, 18, 904-915.	7.8	192
2	Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene, 2003, 22, 660-664.	5.9	179
3	Suppressor of Cytokine Signaling-1 Inhibits VAV Function through Protein Degradation. Journal of Biological Chemistry, 2000, 275, 14005-14008.	3.4	149
4	The tumor suppressor activity of SOCS-1. Oncogene, 2002, 21, 4351-4362.	5.9	123
5	In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood, 2012, 120, 4846-4849.	1.4	89
6	Suppressor of Cytokine Signaling 6 Associates with KIT and Regulates KIT Receptor Signaling. Journal of Biological Chemistry, 2004, 279, 12249-12259.	3.4	71
7	Signal transduction by several KIT juxtamembrane domain mutations. Oncogene, 2003, 22, 4710-4722.	5.9	65
8	Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood, 2006, 108, 1065-1072.	1.4	62
9	Mechanisms of STAT Protein Activation by Oncogenic KIT Mutants in Neoplastic Mast Cells. Journal of Biological Chemistry, 2011, 286, 5956-5966.	3.4	58
10	SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica, 2014, 99, 830-835.	3.5	55
11	Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood, 2010, 116, 1114-1123.	1.4	52
12	The Rho GTP exchange factor Lfc promotes spindle assembly in early mitosis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9529-9534.	7.1	51
13	Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. Experimental Hematology, 2003, 31, 622-630.	0.4	50
14	The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood, 2007, 110, 2593-2599.	1.4	44
15	Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood, 2008, 112, 4039-4047.	1.4	43
16	Suppressor of Cytokine Signaling 1 Interacts with the Macrophage Colony-stimulating Factor Receptor and Negatively Regulates Its Proliferation Signal. Journal of Biological Chemistry, 2001, 276, 22133-22139.	3.4	42
17	Overexpression of suppressor of cytokine signaling-1 impairs pre-T-cell receptor-induced proliferation but not differentiation of immature thymocytes. Blood, 2001, 97, 2269-2277.	1.4	36
18	The E3 ubiquitin ligase HOIL-1 induces the polyubiquitination and degradation of SOCS6 associated proteins. FEBS Letters, 2006, 580, 2609-2614.	2.8	31

#	ARTICLE	IF	CITATIONS
19	FES kinases are required for oncogenic FLT3 signaling. <i>Leukemia</i> , 2010, 24, 721-728.	7.2	28
20	Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma. <i>Journal of Clinical Investigation</i> , 2017, 127, 2310-2325.	8.2	26
21	A Positive Regulatory Role for Suppressor of Cytokine Signaling 1 in IFN- γ -Induced MHC Class II Expression in Fibroblasts. <i>Journal of Immunology</i> , 2002, 169, 5010-5020.	0.8	25
22	KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570. <i>Oncogene</i> , 2014, 33, 872-881.	5.9	23
23	Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology. <i>Nature Communications</i> , 2017, 8, 1420.	12.8	18
24	SARs Do Not Impair Position-Dependent Expression of a kit/LacZ Transgene. <i>Biochemical and Biophysical Research Communications</i> , 1995, 211, 735-741.	2.1	15
25	An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 51163-51173.	1.8	15
26	Multiple neuroendocrine tumours in transgenic mice induced by c-kit-SV40 T antigen fusion genes. <i>Oncogene</i> , 1997, 14, 2661-2670.	5.9	13
27	The Fer tyrosine kinase regulates interactions of Rho GDP-Dissociation Inhibitor a with the small GTPase Rac. <i>BMC Biochemistry</i> , 2010, 11, 48.	4.4	13
28	SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis. <i>Cancers</i> , 2020, 12, 1996.	3.7	11
29	Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT. <i>PLoS ONE</i> , 2016, 11, e0160165.	2.5	8
30	FES kinase participates in KIT-ligand induced chemotaxis. <i>Biochemical and Biophysical Research Communications</i> , 2010, 393, 174-178.	2.1	6
31	Characterization of S628N. <i>JAMA Dermatology</i> , 2014, 150, 1345.	4.1	6
32	GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness. <i>Blood</i> , 2021, 138, 1590-1602.	1.4	4
33	TET2 regulates immune tolerance in chronically activated mast cells. <i>JCI Insight</i> , 2022, 7, .	5.0	4
34	Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance. <i>PLoS ONE</i> , 2021, 16, e0260852.	2.5	2
35	An oncogenomics-based in vivo screen identifies novel melanoma tumor-suppressors. <i>European Journal of Cancer</i> , 2016, 61, S30-S31.	2.8	0
36	Protein Kinases in Leukemias. <i>Cancers</i> , 2021, 13, 2747.	3.7	0